Abstract
A complex treatment of diabetes mellitus type 2 is associated with prolongation of the human life, improvement of it quality and prevention of macro- and microvascular complications. To reach such goals in the treatment of dyslipidemia in diabetes mellitus type 2 with high risk cardiovascular patients is very difficult, despite a diet, life style and pharmacological intervention.
Despite statin treatment, cardiovascular disease residual risk remains high. After LDL the next lipoprotein goal is to increase HDL.
The choice of appropriate combination of hypolipidemic agents and monitoring for possible side effects, tolerance and compliance of patients is necessary, namely because of increased number of drug interactions a side effects of combination therapy. The possible combinations include namely statin + fibrate, and further combination include fibrate + niacin, fibrate + ezetimibe, statin + niacin or + ezetimibe, or omega-3 fatty-acids.